- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05008042
Evaluation of the Efficiacy of Mecobalamine in the Treatment of Long-term Pain in Women Diagnosed With Fibromyalgia
August 20, 2021 updated by: Carina Elmqvist, Linnaeus University
Evaluation of the Efficiacy of Mecobalamine (Vit B12) in the Treatment of Long-term Pain in Women Diagnosed With Fibromyalgia: Single-blind Randomized Controlled Trial With Three-month Follow up
Fibromyalgia causes long term pain where mostly women are affected.
It is not entirely clear how vitamin B12 affects the human pain system, there are however many primary studies that indicate different interesting approaches.
Considering that the receptor of NMDA is involved in both long-term pain and vitamin B12 deficiency its of most importance to evaluate whether vitamin B12 decreases the pain sensitivity and the experience of pain i.e hyperalgesia and allodynia, at persons with fibromyalgia.The aim of this study is therefore to evaluate the effect of Mecobalamin (vitamin B12), and describe lived experiences of pain, health, suffering and well-being in women with diagnosed fibromyalgia.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Carina Elmqvist, Ass prof
- Phone Number: +46772288000
- Email: carina.elmqvist@lnu.se
Study Contact Backup
- Name: Karin Säll Hansson, Master of sc
- Phone Number: +46772288000
- Email: karin.sall_hansson@lnu.se
Study Locations
-
-
Kronoberg
-
Växjö, Kronoberg, Sweden, 352 91
- Recruiting
- Linnaeus University
-
Contact:
- Carina Elmqvist, Ass prof
- Phone Number: +46772288000
- Email: carina.elmqvist@lnu.se
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women aged 20-70 years
- Swedish-speaking
- Diagnosis of fibromyalgia
- Safe method of contraception
- Cobalamin / p (vitamin B12) should be >250 pmol/L < 800 pmol/L
- Given consent to participate.
Exclusion Criteria:
- Previous treatment with B12
- Known hypersensitivity to the active substance Mecobalamin or an additive
- Vegan as veganism can lead to B12 deficiency
- Neuroleptics
- Known heart, kidney or liver disease
- Reynaud's phenomenon (white fingers)
- Known neuropathy (impaired sensation)
- Breastfeeding
- Pregnancy or plan pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Mecobalamine 5 mg/ml
The active substance of vitamin B12 given in the study is Mecobalamin 5mg / ml 2 ml ie 10 mg and is given intramuscularly.
|
The Active substance of vitamin B12 is Mecobalamin 5 mg/ml is given intramuscularly
|
Placebo Comparator: NaCl 9mg/ml
Placebo substance given in the study is Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) given intramuscularly.
|
Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) is given intramuscularly.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerance time
Time Frame: 24 weeks
|
Primary outcome is tolerance time, maximized to Three minutes, tested using the Cold Pressure test
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain experience measured by a pressure algometry test
Time Frame: 24 weeks
|
Pain experience measured by a pressure algometry test performed on the shoulder, hip, knee and elbow.
|
24 weeks
|
Possible pain change measured by a pressure algometry test
Time Frame: 24 weeks
|
Possible pain change measured by a pressure algometry test performed on the shoulder, hip, knee and elbow.
|
24 weeks
|
Subjective experience of pain measured using Numeric Rating Scale (NRS)
Time Frame: 24 weeks
|
Subjective experience of pain measured using Numeric Rating Scale (NRS) 0-10 where 0 is the best outcome .
|
24 weeks
|
Possible pain change measured using Numeric Rating Scale (NRS) 0-10
Time Frame: 24 weeks
|
Possible pain change measured using Numeric Rating Scale (NRS) 0-10 where 0 is the best outcome .
|
24 weeks
|
Ratings of expectation, desire for relief, using Numeric Rating Scale (NRS)
Time Frame: 24 weeks
|
Ratings of expectation, desire for relief, using Numeric Rating Scale (NRS) 0-10 where 0 is the best outcome.
|
24 weeks
|
Ratings of expectation, pain variability, using Numeric Rating Scale (NRS) 0-10
Time Frame: 24 weeks
|
Ratings of expectation, pain variability, using Numeric Rating Scale (NRS) 0-10 where 0 is the best outcome.
|
24 weeks
|
Activity level, assessed using questionnaire McGills Pain Questionnaire (MPQ).
Time Frame: 24 weeks
|
Activity level are assessed using questionnaire McGills Pain Questionnarie (MPQ).
Short version score 0-45.
|
24 weeks
|
Quality of Life are assessed using questionnaires RAND-36.
Time Frame: 24 weeks
|
Quality of life are assessed using questionnaires RAND-36 score 0-100
|
24 weeks
|
Experience of the effect of the drug, assessed using questionnaire Patients´ Global Impression of Change (PGIC).
Time Frame: 24 weeks
|
Experience of the effect of the drug, score 1-7
|
24 weeks
|
Cobalamin in plasma
Time Frame: 24 weeks
|
Control of vitamin B12 is done by measuring cobalamin in plasma.
|
24 weeks
|
Lived experiences of pain, health, suffering and well-being.
Time Frame: 24 weeks
|
Qualitative in-depth interviews will be conducted to capture women's lived experiences of pain, health, suffering and well-being.
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Carina Elmqvist, Ass prof, Linnaeus University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 6, 2019
Primary Completion (Anticipated)
December 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
June 30, 2021
First Submitted That Met QC Criteria
August 9, 2021
First Posted (Actual)
August 17, 2021
Study Record Updates
Last Update Posted (Actual)
August 26, 2021
Last Update Submitted That Met QC Criteria
August 20, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EUDRACT 2015-005086-23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Spaulding Rehabilitation HospitalNot yet recruiting
-
Cairo UniversityNot yet recruiting
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
University of UtahTerminated
-
State University of New York - Upstate Medical...CompletedFibromyalgia, PrimaryUnited States
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
Clinical Trials on Mecobalamin 5 MG
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHand-foot SyndromeChina
-
Eisai Co., Ltd.CompletedPeripheral NeuropathyChina
-
Eisai Co., Ltd.CompletedAmyotrophic Lateral Sclerosis (ALS)Japan
-
Eisai Co., Ltd.CompletedAmyotrophic Lateral Sclerosis (ALS)Japan
-
Eisai Co., Ltd.CompletedDementia With Vitamin B12 DeficiencyChina
-
PfizerCompleted
-
Riphah International UniversityCompleted
-
MajianhuaUnknownDiabetic Peripheral Neuropathy
-
Anesiva, Inc.CompletedTotal Knee Arthroplasty (Replacement)United States
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownInjury of Facial Nerve, Unspecified Side, Initial Encounter